PROVIDENCE, R.I. – Amgen will expand in Rhode Island, with a new $160-million, next-generation biomanufacturing plant that will be the first of its kind in the United States. The facility, which will produce approximately 150 new highly skilled manufacturing jobs, will be supported by incentives from Rhode Island’s innovative toolkit of economic development programs.
“I am thrilled that Amgen is planning to expand and bring new, highly skilled jobs to Rhode Island and further enhance the State’s life sciences community and manufacturing expertise,” said Governor Gina M. Raimondo. “We welcome Amgen’s future health care advancements for patients around the world that will come from this new biomanufacturing plant.”
Amgen’s new biomanufacturing plant will be built on Amgen’s Rhode Island 75-acre campus in West Greenwich and is expected to create approximately 150 additional manufacturing positions and hundreds of construction and validation jobs. The new plant will employ the firm’s next-generation biomanufacturing capabilities and manufacture products for the U.S. and global markets. Today, Amgen employs 625 full-time employees in Rhode Island.
The new biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built in half the construction time with approximately one half of the operating cost required of a traditional plant. Next generation biomanufacturing plants require a smaller manufacturing footprint and offer greater environmental benefits, including reduced consumption of water, energy and lower levels of carbon emissions.
Join our thriving community of 70,000+ superintendents and trade professionals on LinkedIn!
Search our job board for your next opportunity, or post an opening within your company.
Subscribe to our monthly
Construction Superintendent eNewsletter and stay current. 
